# US 2022/0031799 A1 · Methods and compositions for the treatment of sengers syndrome

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031799 A1
- Document ID: US20220031799A1
- Status: Published application
- Kind: A1
- Application number: 17/299,681
- Filed: 2019-12-05
- Published: 2022-02-03
- Earliest claimed: 2018-12-06
- Assignees: Stealth BioTherapeutics Inc.
- Applicants: Stealth BioTherapeutics Inc.
- Inventors: James Carr; Michael Dimatteo; Anthony Abbruscato; Hans Bjornsson
- Web page: https://patentgrep.com/patent/US20220031799A1

## CPC

- A61K 38/07: Tetrapeptides
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/06: Antiarrhythmics
- A61P 9/08: Vasodilators for multiple indications
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- C07K 5/1019: {with the first amino acid being basic}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The disclosure provides methods of preventing or treating Sengers syndrome in a mammalian subject, reducing risk factors associated with Sengers syndrome, and/or reducing the likelihood or severity of Sengers syndrome. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to increase expression of AGK in subjects in need thereof.

## Claims

### Claim 1

A method for treating or preventing Sengers syndrome in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the peptide D-Arg-2′6′-Dmt-Lys-Phe-NH2 or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the subject displays reduced levels of acylglycerol kinase (AGK) expression compared to a normal control subject.

### Claim 3 (depends on 1, 2)

The method of any one of claims 1-2, wherein the peptide is administered daily for 6 weeks or more.

### Claim 4 (depends on 1, 2, 3)

The method of any one of claims 1-3, wherein the peptide is administered daily for 12 weeks or more.

### Claim 5 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the subject has been diagnosed as having Sengers syndrome.

### Claim 6 (depends on 5)

The method of claim 5, wherein the Sengers syndrome comprises one or more of cataracts, hypertrophic cardiomyopathy, reduced cardiac function as assessed by ejection fraction, skeletal myopathy, exercise intolerance, lactic acidosis, neutropenia, tachydyspnea, nystagmus, eosinophilia, cervical meningocele, isolated Complex I deficiency, strabismus, hypotonia, hyporeflexia, delayed motor development, reduced AGK expression, reduced mitochondrial levels of glutamate carrier 1 (GC1), reduced mitochondrial levels of adenine nucleotide transporter type 1 (ANT1), reduced mitochondrial levels of adenine nucleotide transporter type 3 (ANT3), reduced mitochondrial levels of phosphate carrier (PiC), and reduced mitochondrial levels of translocase of the inner membrane 22 (TIM22) subunits (hTim22, Tim29, and hTim9).

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method of any one of claims 1-6, wherein the subject is human.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1-7, wherein the peptide is administered orally, topically, systemically, intravenously, subcutaneously, intraocularly, intraperitoneally, or intramuscularly.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of any one of claims 1-8, further comprising separately, sequentially or simultaneously administering a cardiovascular agent to the subject.

### Claim 10 (depends on 9)

The method of claim 9, wherein the cardiovascular agent is selected from the group consisting of: a diuretic, an angiotensin-converting enzyme (ACE) inhibitor, an angiotensin II receptor blocker or inhibitor, an angiotensin-receptor neprilysin inhibitor (ARNI), an If channel blocker or inhibitor, a beta blocker, an aldosterone antagonist, a hydralazine and isosorbide dinitrate, a diuretic, and digoxin.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method of any one of claims 1-10, wherein the pharmaceutically acceptable salt comprises acetate, hydrochloride or trifluoroacetate salt.

### Claim 12

A method for increasing the expression of AGK in a mammalian subject in need thereof, the method comprising: administering to the subject a therapeutically effective amount of the peptide D-Arg-2′6′-Dmt-Lys-Phe-NH2 or a pharmaceutically acceptable salt thereof.

### Claim 13 (depends on 12)

The method of claim 12, wherein the expression of AGK in the subject is about 2-5 fold less than the level of AGK expression in a normal control subject.

### Claim 14 (depends on 12, 13)

The method of any one of claims 12-13, wherein the peptide is administered daily for 6 weeks or more.

### Claim 15 (depends on 12, 13, 14)

The method of any one of claims 12-14, wherein the peptide is administered daily for 12 weeks or more.

### Claim 16 (depends on 12, 13, 14, 15)

The method of any one of claims 12-15, wherein the subject has been diagnosed as having, is suspected of having, or is at risk of having Sengers syndrome.

### Claim 17 (depends on 16)

The method of claim 16, wherein the Sengers syndrome comprises one or more of cataracts, hypertrophic cardiomyopathy, reduced cardiac function as assessed by ejection fraction, skeletal myopathy, exercise intolerance, lactic acidosis, neutropenia, tachydyspnea, nystagmus, eosinophilia, cervical meningocele, isolated Complex I deficiency, strabismus, hypotonia, hyporeflexia, delayed motor development, reduced AGK expression, reduced mitochondrial levels of glutamate carrier 1 (GC1), reduced mitochondrial levels of adenine nucleotide transporter type 1 (ANT1), reduced mitochondrial levels of adenine nucleotide transporter type 3 (ANT3), reduced mitochondrial levels of phosphate carrier (PiC), and reduced mitochondrial levels of translocase of the inner membrane 22 (TIM22) subunits (hTim22, Tim29, and hTim9).

### Claim 18 (depends on 12, 13, 14, 15, 16, 17)

The method of any one of claims 12-17, wherein the subject is human.

### Claim 19 (depends on 12, 13, 14, 15, 16, 17, 18)

The method of any one of claims 12-18, wherein the peptide is administered orally, topically, systemically, intravenously, subcutaneously, intraocularly, intraperitoneally, or intramuscularly

### Claim 20 (depends on 12, 13, 14, 15, 16, 17, 18, 19)

The method of any one of claims 12-19, further comprising separately, sequentially or simultaneously administering a cardiovascular agent to the subject.

### Claim 21 (depends on 20)

The method of claim 20, wherein the cardiovascular agent is selected from the group consisting of: a diuretic, an angiotensin-converting enzyme (ACE) inhibitor, an angiotensin II receptor blocker or inhibitor, an angiotensin-receptor neprilysin inhibitor (ARNI), an If channel blocker or inhibitor, a beta blocker, an aldosterone antagonist, a hydralazine and isosorbide dinitrate, a diuretic, and digoxin.

### Claim 22 (depends on 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The method of any one of claims 12-21, wherein the pharmaceutically acceptable salt comprises acetate, hydrochloride or trifluoroacetate salt.

### Claim 23

A method for reducing the risk of Sengers syndrome in a mammalian subject having decreased expression of AGK compared to a normal control subject, the method comprising: administering to the subject a therapeutically effective amount of the peptide D-Arg-2′6′-Dmt-Lys-Phe-NH2 or a pharmaceutically acceptable salt thereof.

### Claim 24 (depends on 23)

The method of claim 23, wherein the pharmaceutically acceptable salt comprises acetate, hydrochloride or trifluoroacetate salt.
